Your search did not match any results.
We suggest you try the following to help find what you’re looking for:
With programs specifically developed for Oracle’s regional customer communities, this multifaceted event provides compelling sessions led by Oracle customers and industry thought leaders.
Meet with your peers and gain perspective on industry trends from leading experts on artificial intelligence, cloud-based research, innovative study-site selection/activation/analytics, and additional advances that are transforming and streamlining clinical development.
Has the global pandemic disrupted our journey or cleared the path for us in advancing clinical research? Hear from Oracle Health Sciences SVP and General Manager, Henry McNamara, as he explores the answer to this question.
Oracle Health Sciences SVP and GM
This session will provide an update on both Clinical One and Safety One from both a usage and directional viewpoint. A review of the roadmap and new innovation in both platforms will be covered along with the latest breakthrough on how the One platform is rethinking how to run clinical trials.
Panel session discussing next generation Clinical Trial Management needs and how sponsors and CROs can collaborate on trial management and oversight within the same platform, eliminating data redundancy, integrations and status reporting needs.
Hear our latest strategy to evolve our suite of safety products (Argus, Empirica, and Safety One Intake) to modernize the industry-leading safety applications and bring them closer to Clinical One to form one source of truth across clinical and safety.
This session will spotlight key features of machine learning that are driving effective study planning.
Hear from customers on their experience and innovations utilizing the Clinical One platform for Randomization and Data Collection capabilities; including best practices, time savings and adoption methods for onboarding the platform.
In this panel session, hear from colleagues who have been working on Artificial Intelligence projects around case processing and get their insights on the progress the industry is making, what we have learned, and what they think about the path forward.
Hear from study build experts with experience across multiple solutions such as EDC, DMW, and SAS. Discussion will include current challenges, impact of standards, and potential existing and future solution options, including MDRs and a platform-level designer for Clinical One.
Innovative technologies, including the customization of Activate workflows and the use of Activate data in a document residency dashboard, has resulted in an increase in efficiency and quality, and a reduction of cycle times for PPD Study Start Up.
With the ever increasing volume and complexity of data in clinical trials, there has been an evolution of data management towards data science. In this fireside chat, Pfizer's Demetris Zambas will discuss the challenges they are facing and their vision for data management in the future, including the impact on people, processes, and technology.
Safety One Intake brings machine learning to high-volume case processing, allowing customers to focus human efforts on high-impact activities rather than case intake. Join us to hear about the latest updates and for a brief demo.
In the development of the COVID-19 vaccine, Pfizer departed from traditional clinical development strategies and strove to demolish healthcare disparities and be more inclusive. As a result, the impact on the organization has led to a major paradigm shift in site intelligence, its data and approaches implemented to achieve greater inclusivity. We discuss the approaches implemented at Pfizer and how site intelligence adapted its model to technology to lead in the race for inclusivity.
In the race to develop safe and effective therapies and vaccines for COVID-19, companies innovated to accelerate bringing products to market. In this session, we will explore what we learned from this global effort and apply it to PV initiatives from now on.
In this session, Pfizer will review the pragmatic journey of AI/ML implementation in Clinical development, implementation through investments and how to embrace and capitalize with AI/ML with the Oracle partner ecosystem.
Join us for a discussion about the future of pharmacovigilance operations and systems.
You will hear from a world-renowned bioengineer, surgeon, and investor focusing on the science of regenerative medicine, a practice that aims to refurbish diseased or damaged tissue using the body's own healthy cells. Regenerative medicine repairs and replaces damaged tissues and organs by bioprinting either entire or partial tissues and organs. These miniaturized organs, or organoids, can be engineered to create microphysiological systems and unleash new advances for drug development. These organoid systems can generate critical data to generate insights in drug toxicity, disease modeling, biomarker discovery/validation, and personalized medicine.
W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine
March 30, 2020 set the USA on a path of partnership between federal agencies and private firms to develop, manufacture and distribute COVID-19 vaccines to patients more rapidly while adhering to standards for safety and efficacy. Tune in to hear the impact technology had on the effort to make sure that the logistics are in place for the various jurisdictions.
Keeping pace with real-world health events requires providing the necessary data to decision makers. This panel will reveal how this is repeatedly accomplished so rapidly across the USA amidst diverse environments, processes and systems.
Exploring real-time data flows from all systems providing data sources for each study and modern technologies to deliver Unified eClinical Analytics to do away with traditional siloed analysis views of the Data Sources.
Our Regulations and Audits Working Group stays on top of all of the regulatory impacts facing our customers. In this session, we will present the latest updates for the North American region and global regulators.
From Recruitment to Submission, clinical trials require a myriad of suppliers and service providers. Digitally connecting this broad ecosystem provides major opportunities to enhance, extend and optimize today's processes. Hear from key players in the ecosystem.
In this session, we will take a closer look at near-term updates coming to Argus to meet regulatory needs and evolve its feature set.
Revised activation strategy implementation to improve SSU outcomes within a mid-size CRO in key therapeutics areas and specialty study types.
With a significant effort to evolve to Safety One Argus, join us as we share the effort's approach and progress and how customers can engage deeply to ensure we meet your needs with our next-generation case management system.
CSL to present on their implementation of Select and Activate integration with CTMS & eTMF through a comprehensive integration layer, resulting in end-to-end automated syncing of activities and documents from start-up to closeout.
This session will review the differences between a unified platform and an integrated eClinical platform in detail and why a unified platform brings greater quality and innovation to both the front end and back end office.
Decentralized trials are fast becoming the new norm. This session will explore decentralized trials and the impact on Patients, Sites and Sponsors as well as examine how can we simplify adoption, and maximize this new approach to accelerate research.
This session will showcase the benefits of a unified approach for managing and streamlining your data.
With a growing number of customers adopting the Argus Safety Cloud, join us as we share their journey, including reasons for making a move, lessons learned, and how things are working now that they use the system.
With Empirica Signal and Topics 9.x bringing significant UX enhancements, this session will focus on the benefits customers see in the latest releases.
Explore Oracle Health Sciences solutions and resources.